What you need before approaching a Korean beauty OEM or ODM

The Korea Herald reported estimated Ministry of Food and Drug Safety figures of $11.4 billion in Korean cosmetics exports in 2025, reaching 202 countries, including $2.2 billion to the United States. Those figures describe export scale, not the capabilities of a particular factory. Industry language also varies by supplier, so confirm the actual scope in writing. In broad terms, private label usually starts from an existing formula with limited changes. ODM commonly means the manufacturer contributes product development and formulation. OEM commonly means production follows a brand-owned or brand-directed specification.

The right route depends on what must be proprietary, how quickly the brand needs to launch, available development budget, testing requirements, and the volume the business can responsibly buy.

A useful RFQ lets a manufacturer decide whether the project fits its equipment, formulation library, component network, certifications, capacity, and export experience. Vague requests for a catalog and best price usually create generic answers.

The formula, bottle, pump, cap, decoration, carton, and raw materials can each have different minimums. The highest component minimum may control the project even when the factory can fill a smaller batch. Stock packaging and an existing formula can reduce development work; custom molds, specialty decoration, new actives, SPF, or multiple shades can add minimums, testing and lead time. Confirm the effect in the actual quote.

Commercial sourcing service OEMKorea publishes examples of several thousand units per SKU; these are supplier-market guidance, not a universal minimum. Ask for every component minimum separately, the cost at two or three volume tiers, overage and wastage assumptions, and ownership of leftover components. Distinguish units filled now from components you must pay for now but may use later.

Define the target market before approving the formula and label. An ingredient or claim acceptable in Korea may need different treatment in the United States. Where registration applies, the manufacturer or processor registers the facility; the responsible person handles product listing. Registered foreign facilities must identify a US agent. Have a qualified specialist confirm applicability and exemptions, then assign the MoCRA tasks to the appropriate parties. Product listing is not FDA approval.

The contract should name who supplies each document, owns the formula and test data, maintains records, handles changes and is responsible for final target-market review. For every requested report, identify the formula and packaging it covers, whether it exists or must be commissioned, its price and its delivery date. A sample from a formula library is not proof that your changed product and package have been assessed.

FDA does not issue certificates verifying cosmetic facility registration or product listing. Do not accept an 'FDA certificate' as evidence of product approval or substitute it for the underlying records and applicability review. This is operational guidance, not legal advice.

A useful quote separates bulk, components, decoration, cartons, testing, assembly, freight terms, and optional services. A useful timeline separates brief review, sampling rounds, formula lock, component production, compatibility or stability work, bulk production, filling, quality release, and export.

Communication quality during sampling predicts the production relationship. Document decisions, approve physical standards where possible, define acceptable tolerances, and do not release bulk production before the formula, packaging, artwork, testing plan, and commercial terms are aligned.